Mohammed Eslam, Shiv Kumar Sarin, Vincent Wai‐Sun Wong, Jian-Gao Fan et al.
Metabolic associated fatty liver disease (MAFLD) is the principal worldwide cause of liver disease and affects nearly a quarter of the global population. The objective of this work was to present the clinical practice guidelines of the Asian Pacific Association for the Study of the Liver (APASL) on ...
Xiaodong Zhou, Giovanni Targher, Christopher D. Byrne, Virend K. Somers et al.
Background Fatty liver disease in the absence of excessive alcohol consumption is an increasingly common condition with a global prevalence of ~ 25–30% and is also associated with cardiovascular disease (CVD). Since systemic metabolic dysfunction underlies its pathogenesis, the term metabolic (dysfu...
Mohammed Eslam, Jian‐Gao Fan, Ming‐Lung Yu, Vincent Wai‐Sun Wong et al.
Metabolic dysfunction-associated fatty liver disease (MAFLD) affects over one-fourth of the global adult population and is the leading cause of liver disease worldwide. To address this, the Asian Pacific Association for the Study of the Liver (APASL) has created clinical practice guidelines focused ...
Xufen Zeng, Krista A Varady, Xiangdong Wang, Giovanni Targher et al.
Metabolic dysfunction-associated fatty liver disease (MAFLD) or metabolic dysfunction-associated steatotic liver disease (MASLD), has become the leading cause of chronic liver disease worldwide. Optimal dietary intervention strategies for MAFLD are not standardized. This study aimed to achieve conse...
Gong Feng, Giovanni Targher, Christopher D. Byrne, Yusuf Yılmaz et al.
Background & Aims: This study used the Global Burden of Disease data (2010-2021) to analyze the rates and trends of point prevalence, annual incidence, and years lived with disability (YLDs) for metabolic dysfunction-associated steatotic liver disease (MASLD) in 204 countries. Methods: Total numbers...
Dan‐Qin Sun, Giovanni Targher, Christopher D. Byrne, David C. Wheeler et al.
Background: With the rising global prevalence of fatty liver disease related to metabolic dysfunction, the association of this common liver condition with chronic kidney disease (CKD) has become increasingly evident. In 2020, the more inclusive term metabolic dysfunction-associated fatty liver disea...
Virendra Singh, Arka De, Rohit Mehtani, Paolo Angeli et al.
Gong Feng, Yusuf Yılmaz, Luca Valenti, Wai‐Kay Seto et al.
BACKGROUND: This study utilised the Global Burden of Disease data (2010-2021) to analyse the rates and trends in point prevalence, annual incidence and years lived with disability (YLDs) for major chronic liver diseases, such as hepatitis B, hepatitis C, metabolic dysfunction-associated liver diseas...
Patrick Basu, Krishna Rayapudi, Vincent Wai‐Sun Wong, Kenneth Yan et al.
Purpose: Pegylated Interferon Alfa (PEG IFN-α) and Ribavirin is the standard of care in treatment of Hepatitis C(HCV) with overall Sustained Viral Response (SVR) of 50%. SVR is based on demographics and ethnicity. African Americans and non-white Latinos have poor SVR (27-33%). There is limited data ...